Vitalograph has been nominated as one of the 21 finalists in this year’s Irish Medtech Awards, which recognize excellence in a sector made up of over 450 companies that employ 48,000 people.
The awards are run by the Irish Medtech Association and are part of the Medtech Rising Business Leaders Conference, which will be held in Galway on December 7th.
The vision of the Irish Medtech Association is to strongly position Ireland as a global leader in innovative patient-centred medical technology solutions, helping to set the future global healthcare agenda, with a proven ecosystem that is a major contributor to the economy.
As a finalist in the Digital Health Innovation category, Vitalograph has been recognised for its contribution to empowering research in Chronic Cough, a therapeutic area of unmet need, with currently no FDA-approved therapies.
Vitalograph has researched, developed, and manufactured the VitaloJAK® cough monitoring system, which records and digitises cough sounds. This is a unique and innovative solution that has enabled the impact of chronic cough therapies to be objectively assessed.
Given that chronic cough can occur in up to 5% to 10% of adult patients, there are millions of people worldwide who will stand to benefit from any new therapies and the impact on quality of life, for individuals and society as a whole will be significant.
Through the creation of the VitaloJAK system, and its development of cutting-edge AI technology, Vitalograph is nurturing a highly skilled workforce, that sustains the growth of the company and creates opportunities for future innovation in this sector.
Other finalists in this category include Deciphex, who are experts in remote pathology, and TriMedika, who develop high-performance medical sensor technology. The caliber of all three finalists are a strong indication of the competitive edge the Irish medtech sector has in the area of digital health and paves the way for exciting innovation in this fast-moving industry.